BioNexus Gene Lab Documents
Documents
100
Ticker
BGLC
ISIN
US0906283066
BioNexus Gene Lab SEC Filings
BioNexus Gene Lab Documents 2026
This page contains all official documents and SEC filings for BioNexus Gene Lab stock (BGLC, ISIN: US0906283066). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of BioNexus Gene Lab's regulatory filings.
BioNexus Gene Lab Stock analysis
BioNexus Gene Lab BioNexus Gene Lab Corp. develops and markets non-invasive blood tests for early disease detection, analyzing RNA changes to assess risks for over 11 diseases. The company’s subsidiary, Bionexus Gene Lab Sdn. Bdh., supports these operations. Products are sold to healthcare providers and diagnostic centers seeking advanced, non-invasive testing solutions. The firm targets medical professionals and institutions focused on personalized health management through functional genomics applications. The company generates revenue through the sale of its RNA-based blood tests, which are marketed as tools for early disease risk assessment. Healthcare institutions and diagnostic service providers purchase these tests to enhance their diagnostic capabilities. The focus on non-invasive methods aligns with growing demand for patient-friendly diagnostic technologies in the molecular diagnostics sector. BioNexus Gene Lab Corp. operates with a small team of 5 full-time employees, emphasizing efficiency in product development and marketing. The subsidiary Bionexus Gene Lab Sdn. Bdh. facilitates local operations, though specific market segments are not detailed beyond healthcare providers and diagnostic centers. Revenue streams are derived solely from test sales, with no mention of additional services or partnerships.